[HTML] nih.gov

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study

S Ghandi, A Aflatoonian, N Tabibnejad… - Journal of assisted …, 2011 - Springer
S Ghandi, A Aflatoonian, N Tabibnejad, MHS Moghaddam
Journal of assisted reproduction and genetics, 2011•Springer
Purpose Comparing the effects of metformin or orlistat on hormone, lipid profile and
ovulation status in obese women with polycystic ovary syndrome. Methods A total of 80
women were prospectively recruited to receive either metformin (n= 40) or orlistat (n= 40).
Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at
baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months.
Results There was no significant difference in ovulation between the two treatment groups …
Purpose
Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome.
Methods
A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects’ ovulatory status was assessed after 3 months.
Results
There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.
Conclusions
Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.
Springer
展开收起
被引用次数：52 相关文章 所有 14 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果